What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature that provides access to the same valuation methodology used by Fundamental Research Corp for allocating our firm's capital. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is 4D Molecular Therapeutics, Inc. stock price today?

4D Molecular Therapeutics, Inc. (FDMT) is currently trading at $9.85 USD on NASDAQ. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does 4D Molecular Therapeutics, Inc. do?

4D Molecular Therapeutics, Inc. operates in the Biotechnology sector within Healthcare. 4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's d...

How do I analyze 4D Molecular Therapeutics, Inc. stock performance?

Our Snowflake Analysis provides a visual snapshot of 4D Molecular Therapeutics, Inc. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find 4D Molecular Therapeutics, Inc. financial statements?

Access 4D Molecular Therapeutics, Inc. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC uses the same proprietary valuation model for public stock analysis that we use for allocating our own firm's capital. This means our fair value estimates are based on the same rigorous, data-driven methodology that institutional investors trust. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About 4D Molecular Therapeutics, Inc.

Industry

Biotechnology

Sector

Healthcare

CEO

David H. Kirn

Headquarters

5858 Horton Street, EmeryVille, CA, US

Industry

Biotechnology

Sector

Healthcare

CEO

David H. Kirn

Headquarters

5858 Horton Street, EmeryVille, CA, US

Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.

FDMT•NASDAQ

4D Molecular Therapeutics, Inc.

FDMT•NASDAQ

Market cap

$514.92M

Sentiment

Your view on FDMT

Mkt Cap

$514.92M

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About 4D Molecular Therapeutics, Inc.

Industry: Biotechnology
Sector: Healthcare
CEO: David H. Kirn
Headquarters: 5858 Horton Street, EmeryVille, CA, US

Industry: Biotechnology
Sector: Healthcare
CEO: David H. Kirn
Headquarters: 5858 Horton Street, EmeryVille, CA, US

Description

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News